Efficacy (Preliminary) and Safety of Artificial Salivary Containing Cumin and Ginger Extract in Healthy Volunteer
Launched by CHULALONGKORN UNIVERSITY · Aug 3, 2021
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at the safety and effectiveness of a new artificial saliva that contains extracts from cumin and ginger. Researchers want to see if this new product can help people who may have issues with dry mouth. The study will involve 21 healthy volunteers at first, and then expand to 112 participants who will be divided into two groups: one group will use the new artificial saliva, and the other group will use a standard commercial artificial saliva.
To be eligible for the trial, participants must be over 18 years old, have no current oral health issues, and should not have any allergies to cumin, ginger, or other related substances. They should also not have been using any artificial saliva products for more than two weeks. Participants can expect to help researchers learn more about how this new artificial saliva works and contribute to potential future treatments for people suffering from dry mouth. It's important to note that individuals with certain medical conditions, those who are pregnant or breastfeeding, and anyone currently involved in another study won't be able to participate.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age more than 18 years
- • World Health Organization Oral Mucositis Grading Scale =0
- • No using artificial salivary or activated salivary medicine more than 2 weeks
- • No cumin, ginger, xylitol, glycerin allergy
- • Have a willingness to participate in the study
- Exclusion Criteria:
- • Uncontrolled disease
- • Dry mouth
- • Salivary gland disease, inflammation, or sialolith
- • Pregnancy or lactation
- • During participated in other study
About Chulalongkorn University
Chulalongkorn University, one of Thailand's premier academic institutions, is dedicated to advancing medical research and enhancing healthcare outcomes through innovative clinical trials. With a strong emphasis on collaboration and interdisciplinary approaches, the university leverages its extensive resources and expertise in various medical fields to conduct rigorous scientific investigations. Chulalongkorn University aims to contribute to global health advancements by fostering a culture of excellence in research, education, and community service, ultimately improving patient care and public health standards.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bangkok, , Thailand
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials